NICE rejects GSK's Tyverb as too expensive in second draft recommendation
Tyverb (lapatinib) has been deemed too expensive for use by the UK's National Health Service, despite an offer from drug major GlaxoSmithKline to provide it free to each patient for the first 12 weeks.
In its second appraisal consultation document, the National Institute for Health and Clinical Excellence (NICE), which advises the government on which drugs to cover, agreed with the verdict of an earlier draft recommendation that the oral, dual targeted therapy is too expensive.
"Given our involvement, it is difficult to comment without the appearance of self interest, however we strongly believe that the wrong decision has been made for patients, doctors and the NHS," said Simon Jose, general manager for GSK UK Pharmaceuticals. "We therefore remain committed to working with the NHS and NICE to make this innovative medicine available," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze